January 11, 2018
Thomas Mitchell of Westword published a piece on Jeff Sessions rescinding the Cole Memo and what that means for the protection of the cannabis industry, including hemp and medical cannabis. Front Range Biosciences' CEO and Co-Founder, Dr. Jonathan Vaught, is featured discussing the industrial hemp segment of the article. Read an excerpt from the article below:
"One thing it could eventually do is drive the research and development overseas. You're already seeing countries like Canada, Israel, Australia and countries in South America stepping up to the plate," he says. "It's disappointing, but so much progress has been made that even if the U.S. slows down what it's doing, the international marketplace is going to continue to grow."
You can read the full article here: What the Sessions Memo Means for Hemp, Medical Marijuana and You
In addition, Heather Cabot wrote a piece for Forbes on cannabis industry insiders' wishes for 2018, and Dr. Cecilia Zapata, FRB's Vice President of Nursery, is featured, discussing FRB's continued push to create clean plant starts to further benefit the industry:
"Jeff Sessions' announcement is a big step backwards for the cannabis industry. Many people rely on cannabis as medication and even more could benefit from the plant if it were easily accessible. The industry as a whole has been working tirelessly to advance understanding of the plant, and with states and citizens nation-wide seeing both health and economic benefits from the legal cannabis industry, it's disheartening to see another roadblock being set up with the Cole Memo's repeal. Despite the news, Front Range Biosciences will continue to increase consumer safety through our Clean Stock® program, which we believe benefits all current and future consumers of cannabis."
You can read the full article here: Cannabis Insiders Share 2018 Industry Wishes
Please complete the contact form below to receive our farming recommendations.
